An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

There has been dramatic growth in the number of intravitreal injections performed annually. This paper features expert panel consensus regarding the use of intravitreal injections and serves as an ...

Eylea HD injected every 12 or 16 weeks controls neovascular age-related macular degeneration to a similar extent as Eylea ...

In this expert perspective from Retina 2026, Baruch D. Kuppermann, MD, PhD, discusses positive data from real-world studies ...

Six eyes of 6 patients with VPT who received intravitreal bevacizumab were retrospectively reviewed. All patients received between one and three injections of intravitreal bevacizumab depending upon ...

STOCKHOLM — Simple changes, like minimizing patient visits and reducing the use of nonsterile gloves, can make a big difference in the environmental impact of intravitreal injections without ...

LONG BEACH, Calif. -- Prefilled syringes to treat macular degeneration caused larger and more frequent spikes in intraocular pressure (IOP) as compared with medication drawn from vials, a study of ...

Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive ...

People currently receiving dexamethasone intravitreal implant for the treatment of macular oedema secondary to branch retinal vein occlusion who do not meet the criteria specified in 1.2 above should ...

1.1 Dexamethasone intravitreal implant is recommended as an option for treating visual impairment caused by diabetic macular oedema in adults only if their condition has not responded well enough to, ...